Dementia represents one of the key health and
economic challenges of our time. In the UK it is the leading cause of death,
with an economic cost of over £25 billion per annum, whilst the global
incidence is expected to triple to more than 150 million by 2050. There are no
cures on the horizon, with only four approved symptom-relieving therapies
currently available and several potential disease-modifying treatments in the
pipeline. However, the underlying science is at an inflexion point, with
significant progress being made over recent years in the role of human genetics
in disease risk and trajectory and the molecular characterisation of the
associated biological processes. Technological advances coupled to the
revolution in data science now provide an opportunity to catalyse upon this
scientific progress to bring earlier diagnosis and new treatments in
neurodegenerative conditions to bear.
The UK Government’s 2021 Life Sciences Vision highlights ‘improving
translational capabilities in neurodegeneration and dementia’ as one of its key
healthcare missions. The aim of each Mission is to bring together the best
industrial and academic science, along with the wider sector, to significantly
accelerate the development of new medicines and technologies. The intention is
to be modelled on a Vaccines Taskforce type approach, focussed on making tangible progress on areas
of population health need, with a dedicated budget and accountable leader.
Following extensive engagement between industry
partners, the wider sector and UK Government, an industry-led, not-for profit
entity, the ‘Neurodegeneration Initiative’, is proposed to accelerate the
development of novel precision treatments in neurodegeneration, by developing
innovations in biomarkers, data and digital sciences. It will be co-funded by
government and industry with a clear, accountable leader at its helm. This
entity would work collaboratively and synergistically with other significant
dementia research investments within the UK and internationally to accelerate
the field and provide impact on one of the biggest causes of death globally.
A
figure is required to lead the Neurodegeneration Initiative and fulfil the role
as the Life Sciences Dame Barbara Windsor Dementia and Neurodegeneration Mission Chair. The
appointee will need to work with other leadership figures in the wider dementia
and neurodegeneration ecosystem to ensure effective collaboration and join up
across the whole treatment landscape.
Immediate
objectives of this role will be:
·
Secure
commitment from founding industry partners, including commitment of their
investment.
·
Establish
the set-up of the Initiative, including confirming the operating model, board
membership, and governance arrangements.
·
Put
in place the required resources to run the initiative, including establishing
the executive team and support staff.
·
Begin
to negotiate any fundamental contracts required to get the initiative going in
its first year.
·
Report
on initial progress towards the mission aims and hold the government and
mission partners to account for delivery of Mission commitments.
·
Represent
the Mission and Initiative in relevant (international) forums including through
meetings, workshops and media. Help develop an international presence for the
Mission.
·
Operate
as a key opinion leader and advisor on Neurodegeneration R&D within
Government. This includes working with senior officials across BEIS, DHSC, UKRI
and NIHR to ensure the impact of Neurodegenerative research across the R&D
value chain, and coherency of the Mission within this.
The
role is intended to begin as soon as possible, following the successful
completion of pre-appointment checks and security clearance. We envisage this
role being conducted on a part time basis of approximately 4-8 days a month
over the length of the appointment, but this can also be flexed to a certain
extent around the candidate’s availability and other commitments, and will be
reviewed after an initial time period.
The
post holder should be UK based and able to travel to in person commitments
where helpful and required, but will also be able to work remotely/from their
usual working location. They may in future be expected to work at the location
established for the Initiative once that is established for the portion of
their time commitments devoted to this role.
All
media appearances in the appointee’s capacity as the Dame Barbara Windsor Dementia and Neurodegeneration Mission Chair will be handled by the Office for Life
Sciences.